Argenx
ARGX
#552
Rank
NZ$64.88 B
Marketcap
$1,041
Share price
-3.09%
Change (1 day)
65.71%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Earnings for Argenx (ARGX)

Earnings in 2024 (TTM): -NZ$0.11 Billion

According to Argenx 's latest financial reports the company's current earnings are NZ$1.85 Billion. In 2023 the company made an earning of -NZ$0.54 Billion, an increase over its 2022 earnings that were of -NZ$1.28 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Argenx from 2013 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -NZ$0.11 Billion-79.87%
2023 -NZ$0.54 Billion-58.25%
2022 -NZ$1.28 Billion
2019 -NZ$0.35 Billion124.95%
2018 -NZ$0.16 Billion132.04%
2017 -NZ$66.8 Million54.86%
2016 -NZ$43.14 Million33%
2015 -NZ$32.43 Million13.63%
2014 -NZ$28.55 Million46.25%
2013 -NZ$19.52 Million